Recently, Luzitin has initiated a clinical trial with a new drug, Redaporfin, which has already obtained very significant positive results in the treatment of several types of cancer, namely head and neck cancer. This was the first Portuguese cancer drug to reach the clinical trials phase and is expected to reach the market within five years.
In its 23rd Anniversary, Diário as Beiras, recognized the excellence, talent and quality of companies, personalities and events of the Portugal´s Center Region.
